Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel label

Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel

Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

  • For external use only.

Do not use

on damaged or broken skin.

When using this product

keep out of eyes.  Rinse with water to remove.

Stop use and ask a doctor

if rash occurs.

Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

Do not use

on damaged or broken skin.

Stop use and ask a doctor

if rash occurs.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

  • Helps prevent sunburn

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel Manufacturers

  • Guerlain
    Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel | Guerlain
    No Recall

    Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel | Guerlain

    Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel | Guerlain

    Shake well before use

    For sunscreen use:

    Apply liberally 15 minutes before sun exposure. Reapply at least every two hours. Use a water resistant sunscreen if swimming or sweating. Sun protection measures.  Spending time in the sun increases your risk of skin cancer and early early skin aging.  To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including:     Limit time in the sun, especially from 10 a.m. - 2 p.m.     Wear long-sleeved shirts, pants, hats and sunglasses Children under 6 months:  Ask a doctor.
  • Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel | Ranbaxy Pharmaceuticals Inc.
    No Recall

    Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel | Ranbaxy Pharmaceuticals Inc.

    Lingerie De Peau Invisible Skin-fusion Foundation With Sunscreen Broad Spectrum Spf 20 03 Beige Naturel | Ranbaxy Pharmaceuticals Inc.

    Levocetirizine dihydrochloride is available as 5 mg breakable (scored) tablets, allowing for the administration of 2.5 mg, if needed. Levocetirizine dihydrochloride tablets can be taken without regard to food consumption.

    2.1 Adults and Children 12 Years of Age and Older

    The recommended dose of levocetirizine dihydrochloride tablets is 5 mg (1 tablet) once daily in the evening. Some patients may be adequately controlled by 2.5 mg (1/2 tablet) once daily in the evening.

    2.2 Children 6 to 11 Years of Age

    The recommended dose of levocetirizine dihydrochloride tablets is 2.5 mg (1/2 tablet) once daily in the evening. The 2.5 mg dose should not be exceeded because the systemic exposure with 5 mg is approximately twice that of adults [see Clinical Pharmacology (12.3)].

    2.4 Dose Adjustment for Renal and Hepatic Impairment

    In adults and children 12 years of age and older with:

    • Mild renal impairment (creatinine clearance [CL CR] = 50 to 80 mL/min): a dose of 2.5 mg once daily is recommended; • Moderate renal impairment (CL CR = 30 to 50 mL/min): a dose of 2.5 mg once every other day is recommended; • Severe renal impairment (CL CR = 10 to 30 mL/min): a dose of 2.5 mg twice weekly (administered once every 3 to 4 days) is recommended; • End-stage renal disease patients (CL CR < 10 mL/min) and patients undergoing hemodialysis should not receive levocetirizine dihydrochloride tablets.

    No dose adjustment is needed in patients with solely hepatic impairment. In patients with both hepatic impairment and renal impairment, adjustment of the dose is recommended.